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Fixed-Dose Combination Therapy (Polypill)
for the Prevention of Cardiovascular Disease
Mark D. Huffman, MD, MPH; Angharad N. de Cates, BMBCh, BA; Shah Ebrahim, DM
Fixed-dose combination therapy (polypill) combines low-dose
bloodpressure–andcholesterol-loweringmedicationswithorwith-
out aspirin intoa singlepill for cardiovascular disease (CVD)preven-
tion. A polypill has potential utility in low-resource settings be-
cause it increases adherence at potentially lower cost.1 This JAMA
Clinical Evidence Synopsis summarizes a Cochrane review2 assess-
ing the association of polypills on cardiovascular diseases.
Summary of Findings
The9 trials (N = 7047) included6differentdrugcombinations. The
3 largest trials included 78% of all participants across the studies.
The follow-up period was 12 weeks or less in 6 trials, and 12 to 15
months in the remaining 3 trials. Only 2 trials reported rates of all-
cause mortality (n = 3465) and fatal and nonfatal CVD events
(n = 2479). Two trials included at least 10% of participants with
prevalent CVD at baseline.
The intervention group was associated with decreases in sys-
tolic bloodpressure of 13.4mmHgvs6.3mmHg in the comparator
group (Table). The intervention group was associated with a 33.3
mg/dLdecrease inmeantotal cholesterol vsadecreaseof4.3mg/dL
in thecomparatorgroup.Onesecondaryprevention trial (n = 2004)
reporteddifferences in adherence at 15months (86% for interven-
tion vs 65% for comparator; relative risk [RR], 1.33 [95% CI, 1.26-
1.41]).
The polypill was associated with a higher adverse event rate
compared with the comparator group. Seven trials (n = 4864) re-
ported adverse events. Adverse event rates were higher in partici-
pants randomized to thepolypill comparedwithcomparator (29.7%
[739/2485 participants] for polypill vs 24.2% [576/2379] for com-
parator; RR, 1.19 [95% CI, 1.09-1.30]). The 3 most commonly re-
ported adverse events in the intervention and comparator groups
were increased liver chemistries (7.8% for intervention vs 7.6% for
comparator,P = .91), cough (6.4%for interventionvs3.5%for com-
parator,P = .002), andmyalgias (4.0%for intervention vs 3.6%for
comparator, P = .55).
All-cause mortality was low in both study groups (1.2% [22/
1781] for intervention compared with 1.0% [17/1684] for com-
parator), and there was no association of decreased mortality in
the intervention group compared with the comparator group (RR,
1.26 [95% CI, 0.67-2.38]). Fatal and nonfatal CVD event rates
were 4.0% [50/1243] in the intervention group vs 2.9% [36/
1236] in the comparator group (RR, 1.38 [95% CI, 0.91-2.10]). No
differences in serious adverse events were reported. There was
no difference in quality of life (1 trial, n = 2004). No trials
reported cost outcomes.
Discussion
Polypills are associated with lower blood pressure and cholesterol
comparedwithusual care, active comparators, or placebo,which is
CLINICAL QUESTION Is fixed-dose combination therapy (polypill) that combines antiplatelet,
blood pressure–lowering, and cholesterol-lowering medications into a single pill associated
with improved cardiovascular disease (CVD) risk factors or reduced all-cause mortality or fatal
and nonfatal CVD events? Is the polypill associated with an increase in adverse events?
BOTTOM LINE Polypills are associated with greater reductions in systolic blood pressure and
total cholesterol compared with usual care, placebo, or active comparators, but also with a
19% higher risk of any adverse event. Due to limited power from available evidence, the
association of polypills with all-cause mortality or fatal and nonfatal CVD events is uncertain.
Evidence Profile
No. of randomized clinical trials: 9 trials (7 primary prevention;
2 secondary prevention)
Studyyears:Conducted, 2006-2012;published, 2009-2013; endof
literature search, July 19, 2013
No. of participants: 7047
Men: 4463 (63.3%) Women: 2584 (36.7%)
Race/ethnicity:Not available
Age range, mean (SD): 52.6 years (9.6) to 62.1 years (10.4)
Settings:Outpatient
Countries: International (5 continents)
Drug classes included:Aspirin, blood pressure–lowering drugs, and
a lipid-lowering drug (exclusively statins)
No.ofdrugcombinations:2drugs (3 trials), 4drugs (5 trials), 5drugs
(1 trial)
Comparator groups: Usual care (3 trials), placebo (4 trials), active
comparator (2 trials)
Follow-up:12weeks in6trials; 12-15months in the remaining3trials
Primaryoutcomes:All-causemortality; fatal andnonfatal cardiovas-
cular disease events; adverse events
Secondary outcomes: Change in total and low-density lipoprotein
(LDL)cholesterol concentration,change insystolicanddiastolicblood
pressure, adherence, health-related quality of life, and costs
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likely to be driven by increased adherence, particularly when com-
pared with active comparators or usual care. The trials were not
plannedwith statistical power to evaluate effects on all-causemor-
talityand fatal andnonfatalCVDevents.Polypills areassociatedwith
greater adherence in patients with low baseline adherence com-
paredwithpatientswhoalreadyhavehighadherence.4Rather than
replace usual care for CVD prevention, polypills will likely be a use-
ful adjunct.
Limitations
Five of the included trials had amoderate to high risk of bias,which
reduces the overall quality of evidence. Long-term adherence and
clinical event rates remain tobedetermined. Therewas substantial
heterogeneity thatwasnotexplainedbyeitherasingle trial, thenum-
berof drugs in the interventiongroup, orprimaryvs secondarypre-
vention trials. Pooled results should be viewed with caution.
Comparison of FindingsWith Current Practice Guideline
Clinical practice guidelines have adopted blood pressure–lowering
combination therapy forhypertensionmanagement,5butwedonot
know of any guidelines that recommend polypills for CVD preven-
tion. Polypills arenotpart of theWorldHealthOrganization’sModel
List of Essential Medicines to date.6
Areas in Need of Future Study
Ongoing trials of polypills will likely inform end points of all-cause
mortality, fatal and nonfatal CVD events, quality of life, and costs,
whichmay inform future regulatory decisions and guidelines.
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Table. Summary of Findings of Fixed-Dose Combination Therapy (Polypill) vs Usual Care, Active Comparator, or Placebo (Comparator) by Outcomea
Comparatorb Polypill
Relative Risk
(95% CI)
No. of
Participants
(No. of
Studies) GRADEc
Rationale for
Downgrading Quality
of Evidenced
Total
Participants
No. of Events
(%)
Total
Participants
No. of Events
(%)
Categorical Outcomes
All-cause mortality 1684 17 (1.0) 1781 22 (1.2) 1.26
(0.67 to 2.38)
3465 (2) Low Risk of bias; imprecision
of effect
CVD event 1236 36 (2.9) 1243 50 (4.0) 1.38
(0.91 to 2.10)
2479 (2) Low Risk of bias; imprecision
of effect
Any adverse event
(6 wk-15mo)
2379 576 (24.2) 2485 739 (29.7) 1.19
(1.09 to 1.30)
4864 (7) Low Risk of bias; indirectness
of evidence
Discontinuation
(for any reason)
1307 150 (11.5) 1116 156 (14.0) 1.26
(1.02 to 1.55)
2423 (6) Low Risk of bias; indirectness
of evidence
Continuous Outcomes
Mean Change
(Range)
Mean Change
(Range)
Weighted Mean
Difference
(95% CI)
Systolic blood
pressure, mm Hg
2837 −6.3
(0 to −26.9)
2950 −13.4
(−3.7 to −28.8)
−7.02
(−10.18 to
−3.87)
5787 (9) Moderate Risk of bias; unexplained
heterogeneity
Total cholesterol,
mg/dL
2636 −4.3
(7.0 to −38.7)
2933 −33.3
(−3.9 to −56.8)
−0.75
(−1.05 to −0.46)
5569 (9) Low Risk of bias; unexplained
heterogeneity; funnel
plot asymmetry
LDL cholesterol,
mg/dL
2531 −1.2
(5.0 to −7.0)
2834 −32.1
(−5.8 to −54.1)
−0.81
(−1.09 to −0.53)
5365 (8) Moderate Risk of bias; unexplained
heterogeneity
Abbreviations: CVD, cardiovascular disease; GRADE, Grading of
Recommendations Assessment, Development, and Evaluation; LDL,
low-density lipoprotein.
a Source: data adapted with permission fromWiley.2
bComparator included usual care, placebo, or active comparator.
c Quality of the evidence: moderate quality, further research is likely to
influence the confidence in the estimate of effect andmay change the
estimate; low quality, further research is very likely to influence the confidence
in the estimate of effect and is likely to change the estimate.
dRationale per GRADEmethodology.3
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